GEN Exclusives

More »

The Lists

More »
Jan 8, 2013

Top 25 M&A Deals of 2012

Who bought who last year? Find out here.

Top 25 M&A Deals of 2012

Big bucks were spent on M&As last year. Read on to find out which deal was worth the most. [© Ben Chams -]

  • #12. Ardea

    Acquired by: AstraZeneca

    Price: $1.26 billion

    Deal Completed: June 19

    Premium: 54%

  • #11. Fougera

    Acquired by: Novartis

    Price: $1.525 billion

    Deal Completed: July 23

    Premium: N/A

  • #10. Par Pharmaceuticals

    Acquired by: TPG Capital

    Price: $1.9 billion

    Deal Completed: Sept. 28

    Premium: 37%

  • #9. Dako

    Acquired by: Agilent Technologies

    Price: $2.2 billion

    Deal Completed: June 21

    Premium: N/A

  • #8. Inhibitex

    Acquired by: Bristol-Myers Squibb

    Price: $2.5 billion

    Deal Completed: Feb. 13

    Premium: 163%

  • #7. Medicis

    Acquired by: Valeant Pharmaceuticals

    Price: $2.6 billion

    Deal Completed: Dec. 11

    Premium: 39%

  • #6. Boston Biomedical

    Acquired by: Dainippon Sumitomo Pharma

    Price: $2.63 billion9

    Deal Completed: April 24

    Premium: N/A

  • #5. Human Genome Sciences

    Acquired by: GlaxoSmithKline

    Price: $3 billion

    Deal Completed: Aug. 3

    Premium: 99%

  • #4. Gen-Probe

    Acquired by: Hologic

    Price: $3.8 billion

    Deal Completed: Aug. 1

    Premium: 20%

  • #3. Amylin Pharmaceuticals

    Acquired by: Bristol-Myers Squibb

    Price: $5.3 billion10

    Deal Completed: Aug. 8

    Premium: 101%

  • #2. Actavis Group

    Acquired by: Watson Pharmaceuticals11

    Price: $5.547 billion11

    Deal Completed: Oct. 31

    Premium: N/A

  • #1. Pharmasset

    Acquired by: Gilead Sciences

    Price: $11.2 billion

    Deal Completed: Jan. 17

    Premium: 90%

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »